COVID-19 Pandemic to Offer an Opportunity for the UK Biologics Market

UK biologics market is estimated to grow at a CAGR of 7.8% during the forecast period. COVID-19 pandemic is expected to offer an opportunity for market growth. In October 2020, Cobra Biologics (Cobra), a contract development and manufacturing organization (CDMO) engaged in the manufacturing of pharmaceuticals and biological materials, and Scancell Holdings plc, a developer of new immunotherapies to treat infectious disease and cancer, declared that they have entered into a partnership agreement in which Cobra will produce Scancell’s COVID-19 vaccine. 

Browse the full report description of "UK Biologics Market Size, Share & Trends Analysis Report, By Product (Antibody Therapeutics, Vaccines, Cell Therapy, Gene Therapy, and Others), By Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/uk-biologics-market

This agreement comprises Good Manufacturing Practice (GMP) for plasmid DNA manufacturing that is required to produce the DNA vaccine for SARS-CoV-2 treatment, for application in Phase 1 clinical trial in 2021. Scancell’s COVID-19 vaccine has the efficiency to offer long-lasting immunity to fight against COVID-19. Rising manufacturing of plasmids to large scale and as per the GMP needs management of the scale-up process aims to ensure that plasmids have therapeutic-grade quality. Such kinds of use of biologics in the era of COVID-19 is expected to offer significant scope for market growth.

Scope of the UK Biologics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Product and Application
• Competitive Landscape- AstraZeneca plc, AbbVie Inc., GlaxoSmithKline plc, F. Hoffman-La Roche AG, and Boehringer Ingelheim GmbH

Recent Strategic Initiatives in the UK Biologics Market

• In May 2020, Crescendo Biologics Ltd. and Cancer Research UK declared a Clinical Development Partnership to advance one of Crescendo’s novel bispecific Humabody immunotherapies, CB213, into clinical trials that target cancers of high unmet medical requirements. Under the agreement, Cancer Research UK will fund in the future Phase I clinical trial for CB213, in patients suffering from solid tumors. 
• In March 2019, Roche declared the European Commission approval of MabThera (rituximab) to treat adults suffering from moderate to severe pemphigus vulgaris (PV). It is the first biologic therapy approved by the European Commission for PV and the first key innovation in the treatment of the condition in over 60 years. In June 2018, it was approved by the US FDA and after this approval, MabThera is now approved for the treatment of four autoimmune diseases in the US and Europe.

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

        ? Recovery Timeline

        ? Deviation from the pre-COVID-19 forecast

        ? Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Biologics Market-Segmentation

By Product

• Antibody Therapeutics
• Vaccines
• Cell Therapy
• Gene Therapy
• Others

By Application

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/uk-biologics-market